FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial. PMID 39929221 · Lancet Haematol · 2025-Mar The record is an original result report of an oncology, human, drug-intervention trial. However, it is excluded because it is a Phase I/II single-arm trial (not randomized and not Phase III/IIIb or Phase II/III) and its primary efficacy endpoints are response rates (major cytogenetic response, major haematological response), not time-to-event outcomes (OS, PFS, DFS, etc., Kaplan-Meier, or HR). |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial. PMID 39923680 · Gynecol Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Anesthesia-induced electroencephalogram oscillations and perioperative outcomes in older adults undergoing cardiac surgery. PMID 39921932 · J Clin Anesth · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trial. PMID 39919775 · Lancet Haematol · 2025-Mar While the study meets criteria for oncology, human subjects, randomization, Phase 3, and a time-to-event primary endpoint (DFS), the intervention is a transplant graft strategy (haploidentical PBSCs plus bone marrow vs. PBSCs plus unrelated cord blood) and does not involve a drug-containing intervention as required by the cohort definition. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Impact of Atorvastatin on Intraprostatic Biomarkers - Prognostic Value of 3LS-score - Follow-up of ESTO1-Trial. PMID 39919693 · Neoplasia · 2025-Mar The record describes a randomized trial of atorvastatin in prostate cancer with time-to-event outcomes, but the trial phase is not confirmed as Phase III/IIIb or Phase II/III. The study is primarily a biomarker-focused trial (impact on intraprostatic biomarkers, prognostic value of 3LS-score), and while it reports long-term clinical outcomes, the primary objective is not drug efficacy in a definitive Phase III setting. Therefore, it does not meet the strict eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Pressure pain threshold and perceived impact of pain differentially predict short-term and long-term pain reduction following acupuncture in fibromyalgia. PMID 39915157 · J Integr Med · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design. PMID 39911057 · Future Oncol · 2025-Mar This is a protocol for a Phase 3 randomized trial in oncology with a drug intervention, but the primary endpoints are spleen volume reduction and total symptom score. No time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) is reported or indicated as a primary/key secondary endpoint. It is a protocol-without-results. |
H
|
仅历史库存 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Successes and failures: the latest advances in the clinical development of amyloid-β-targeting monoclonal antibodies for treating Alzheimer's disease. PMID 39908579 · Expert Opin Biol Ther · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Neuroendocrine cervical carcinomas: genomic insights, controversies in treatment strategies, and future directions: a NeCTuR study. PMID 39903954 · Int J Gynecol Cancer · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. PMID 39900091 · Lancet Respir Med · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials. PMID 39894025 · Lancet Oncol · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Author Correction: Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial. PMID 39891005 · Nat Med · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Role of Serum Free Fatty Acids in Endothelium-Dependent Microvascular Function. PMID 39888728 · Endocrinol Diabetes Metab · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis. PMID 39882614 · Circ Heart Fail · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of lemborexant on sleep architecture in participants with insomnia disorder and mild obstructive sleep apnea. PMID 39879708 · Sleep Med · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Safety and Efficacy of Lotilaner Ophthalmic Solution (0.25%) in Treating Demodex Blepharitis: Pooled Analysis of Two Pivotal Trials. PMID 39873946 · Ophthalmol Ther · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of long-acting muscarinic antagonists in COPD: A meta-analysis and meta-regression with a focus on aging. PMID 39870144 · Respir Med · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. PMID 39870096 · Lancet Diabetes Endocrinol · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making. PMID 39869260 · BioDrugs · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Cost-minimization analysis of the GORTEC 2014-04 randomized phase II study of stereotactic ablative radiotherapy (SABR) or chemotherapy-SABR in oligometastatic head and neck cancer. PMID 39837424 · Radiother Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis. PMID 39827019 · Eur Urol · 2025-Mar 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study. PMID 39815052 · Leukemia · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Xenogeneic platelet-rich plasma lotion for preventing acute radiation dermatitis in patients with breast cancer undergoing radiotherapy: An open-label, randomized controlled trial. PMID 39811585 · JPRAS Open · 2025-Mar The study is an oncology human randomized trial with a primary result, but the intervention is a non-drug device/lotion (XONRID® gel is a medical device, PRP lotion is a biological product) and the primary efficacy endpoints are acute radiation dermatitis rates (categorical toxicity), pain scores, and quality-of-life indices, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303. PMID 39809075 · J Geriatr Oncol · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study. PMID 39808408 · Target Oncol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Meta-Analysis of Placebo-Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials. PMID 39807647 · Aliment Pharmacol Ther · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of Frailty on Antihypertensive Treatment in Older Adults. PMID 39807596 · Hypertension · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Human leukocyte antigen alloimmunization in a randomized trial of amustaline/glutathione pathogen-reduced red cells in complex cardiac surgery patients. PMID 39801369 · Transfusion · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Heart failure outcomes captured by adverse event reporting in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial. PMID 39792342 · Eur J Heart Fail · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study. PMID 39789153 · Br J Cancer · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Perspective on the MARS2 Trial. PMID 39772349 · J Thorac Oncol · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Outcome following pylorus resecting pancreaticoduodenectomy versus classical Whipple's pancreaticoduodenectomy: a randomised controlled trial. PMID 39757070 · HPB (Oxford) · 2025-Mar The study is a randomized controlled trial comparing two surgical techniques (pylorus resecting vs. classical pancreaticoduodenectomy) for pancreatic cancer. It meets oncology, human, randomized, and original result criteria. However, it is not a Phase III or definitive trial (phase is not specified), lacks a drug-containing intervention (surgical procedure only), and the primary endpoint is a short-term postoperative complication (delayed gastric emptying), not a time-to-event efficacy endpoint like OS or PFS. Therefore, it does not meet the eligibility criteria for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. PMID 39756424 · Lancet Respir Med · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of telemedicine support for intraoperative anaesthesia care on postoperative outcomes: the TECTONICS randomised clinical trial. PMID 39753404 · Br J Anaesth · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Priors and decision thresholds in phase 2 and phase 3 randomized controlled trials evaluating drug efficacy using Bayesian methods: a systematic review. PMID 39724990 · J Clin Epidemiol · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma. PMID 39722558 · CPT Pharmacometrics Syst Pharmacol · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies. PMID 39717993 · J Diabetes Sci Technol · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Reference Ranges and Determinants of Thyroid Function and TSH Receptor Antibodies During Early Pregnancy in Nepal. PMID 39676726 · Clin Endocrinol (Oxf) · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial. PMID 39674388 · Bone · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Early vs later non-vitamin K antagonist oral anticoagulants in patients with acute ischemic stroke and atrial fibrillation: A meta-analysis and systematic review of randomized trials. PMID 39672479 · Heart Rhythm · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effects of narrative versus non-narrative pictorial warning labels on visual attention and alcohol-related cancer risk perceptions: An eye-tracking study. PMID 39671807 · Addict Behav · 2025-Mar The record describes a randomized eye-tracking study on alcohol warning labels and cancer risk perceptions, not a clinical trial with a drug intervention or a time-to-event efficacy endpoint. Therefore, it does not meet the core eligibility criteria. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial. PMID 39671538 · J Clin Oncol · 2025-Mar The record describes a randomized Phase II oncology trial with a drug/supplement intervention (fish oil) and a primary biomarker endpoint (Ki-67). It is not a Phase III/IIIb trial, and the primary endpoint is not a time-to-event efficacy outcome. Therefore, it does not meet the eligibility criteria. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Extending the time window for tenecteplase by effective reperfusion of penumbral tissue in patients with large vessel occlusion: Rationale and design of a multicenter, prospective, randomized, open-label, blinded-endpoint, controlled phase 3 trial. PMID 39654273 · Int J Stroke · 2025-Mar 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Sarcoma: Last Year's Practice Changing Papers. PMID 39648237 · Ann Surg Oncol · 2025-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Patient-reported outcomes in non-small cell lung cancer: psychometric evaluation of the PROMIS PF-SF 8c and NSCLC-SAQ in two phase 3 clinical trials. PMID 39636512 · Qual Life Res · 2025-Mar The report is a psychometric evaluation of patient-reported outcome (PRO) measures (PROMIS PF-SF and NSCLC-SAQ) using data from two Phase 3 trials. It does not report time-to-event efficacy outcomes (OS, PFS, etc.) or analyze drug intervention efficacy. The publication type and content indicate a methodological/psychometric study, not a primary efficacy result report. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of lemborexant in subjects with insomnia disorder receiving medications for depression or anxiety symptoms. PMID 39632341 · Neuropsychopharmacol Rep · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of KH903 Plus FOLFIRI as a Second-Line Treatment in Unresectable Recurrent or Metastatic Colorectal Cancer: A Randomized Phase 2 Study. PMID 39632230 · Clin Colorectal Cancer · 2025-Mar 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Dupilumab Efficacy and Safety in Children With Moderate to Severe Asthma and High Blood Eosinophils: A Post Hoc Analysis of VOYAGE. PMID 39613097 · J Allergy Clin Immunol Pract · 2025-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Quality of life in advanced-stage, asymptomatic, non-bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful-waiting. PMID 39604791 · Br J Haematol · 2025-Mar The record describes a Phase III randomized trial in follicular lymphoma with a drug intervention (rituximab). However, the reported results are focused exclusively on quality of life outcomes, which are not time-to-event efficacy endpoints as required for inclusion. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Influence of the type of anaesthesia on acute kidney injury after nephrectomy: a randomised controlled trial. PMID 39592204 · Anaesthesia · 2025-Mar The record is a randomized trial in oncology patients with a drug intervention, but the primary efficacy endpoint is acute kidney injury (a safety/toxicity endpoint), not a time-to-event oncologic efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). No time-to-event data (Kaplan-Meier, HR) are reported for any oncologic endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |